ImmunoVaccine Technologies Inc. (IVT), a vaccine development company, today announced receipt of patent approval from the Japanese Patent Office for its vaccine platform.
The specific patent, vaccines with enhanced immune response and methods for their preparation, claims broad exclusivity that an effective, long-term immune response to treat a disease can be produced using a vaccine comprising of an antigen, an adjuvant, vesicles known as liposomes, and a hydrophobic carrier.
"We have a novel technology that enhances vaccines dramatically, so receiving patent approval is important in protecting our competitive advantage," commented Dr. Marc Mansour, vice president of R&D at IVT.
Securing broad patent coverage is part of IVT’s strategy to maximize the market potential of its VacciMax® platform in the largest pharmaceutical markets in the world, including the US, Europe, Canada, Australia and Japan. The company’s VacciMax® technology is based on a novel approach to the use of liposomes in an oil emulsion. IVT has discovered that liposomes, stabilized in the VacciMax® technology, significantly enhance antibody production, creating a more rapid immune response, following a single vaccination. The responses are also long lasting, without requiring booster immunizations.
"The issuance of the patent in Japan complements the US and European patents for our vaccine platform technology," said Dr. Randal Chase, president and CEO of IVT. "We are watching the growth of the Asian market, and patent coverage in Japan is an important step in contributing to the wide reach of our vaccine products."
About IVT (WWW.IMMUNOVACCINE.COM)
ImmunoVaccine Technologies Inc. is a private, clinical-stage, vaccine development company. Through its own biotech research, patented VacciMax® and DepoVax™ technologies, and collaborations with partners, IVT creates vaccines with the potential to help save and improve lives around the world.
In December 2007, IVT signed a binding MOU to acquire Pennsylvania-based Immunotope Inc. The acquisition enables IVT to create an entire pipeline of proprietary therapeutic cancer and infectious-disease specific vaccines. In January 2008, IVT licensed its technology to Pfizer Animal health, marking a pivotal step in achieving its vision of delivering breakthrough vaccines.
For more information, please contact:
Brian Lowe, Vice President
ImmunoVaccine Technologies Inc.
Jennifer Ayotte, Communications
Halifax, Nova Scotia, August 5, 2008